Capsaicin 8% Patch for Spinal Cord Injury Focal Neuropathic Pain, a Randomized Controlled Trial
Pain Medicine · 04.01.2023 · 24 (1) · 71-78
DOI: 10.1093/pm/pnac104 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pain Medicine, online erschienen am 07.07.2022. Verfasst von Adedeji Olusanya und 18 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA. Hauptthemen laut MEDLINE: Neuralgia, Spinal Cord Injuries. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Foundation for Physical Medicine and Rehabilitation.
Abstract (Originalsprache)
Background
Neuropathic pain (NP) after spinal cord injury (SCI) exacerbates disability, decreases quality of life (QOL), and is often refractory to available therapies. Patients report willingness to trade potential recovery of strength, bowel, bladder, or sexual function for pain relief. One proposed mechanism causing NP is up-regulation of transient receptor potential vanilloid 1 (TRPV 1) proteins in uninjured C fibers and dorsal root ganglia causing neuronal excitability. Recent studies have found up-regulation of TRPV 1 proteins after SCI.
Objective
We hypothesize the application of capsaicin 8% patch (C8P), FDA approved for NP in diabetic peripheral neuropathy and post-herpetic neuralgia, will improve pain, function and QOL in persons with SCI.
Methods
Randomized single-blind crossover design in which 11 persons with SCI and NP refractory to two oral pain medications received C8P or a control low dose Capsaicin 0.025% patch (CON) over two 12-week periods. Pain (VAS, MPI-SCI), quality of life (WHO-QOL), and functional status (SCIM) were measured at 2–4-week intervals.
Results
There was a main treatment effect of C8P over CON on VAS and MPI-SCI outcomes with pain reduction of 35% and 29% at weeks 2 and 4, respectively. C8P also demonstrated a main treatment effect over CON on the SCIM mobility subscale. WHO-QOL scores did not improve with C8P.
Conclusions
C8P improves pain and mobility for patients with SCI and refractory NP. Larger studies should be performed to evaluate impact of repeat applications and QOL outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
- University of the Incarnate World Osteopathic Medical School, San Antonio, Texas, USA.
- Department of Orthopedics and Physical Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
- Physical Medicine and Rehabilitation, UTHSC at San Antonio, San Antonio, Texas, USA.
ORCID-Profile: Adedeji Olusanya, Ameet S Nagpal
Förderung
- Foundation for Physical Medicine and Rehabilitation
Zitieren
APA
Olusanya, A., Yearsley, A., Brown, N., Braun, S., Hayes, C., Rose, E., Connolly, B., Dicks, M., Beal, C., Helmonds, B., Peace, W., Kirkman, B., Nguyen, C., Erickson, J., Nguyen, G., Lukose, E., Koek, W., Nagpal, A. S., & Trbovich, M. (2023). Capsaicin 8% Patch for Spinal Cord Injury Focal Neuropathic Pain, a Randomized Controlled Trial. Pain Medicine, 24(1), 71-78. https://doi.org/10.1093/pm/pnac104
Vancouver
Olusanya A, Yearsley A, Brown N, Braun S, Hayes C, Rose E, et al. Capsaicin 8% Patch for Spinal Cord Injury Focal Neuropathic Pain, a Randomized Controlled Trial. Pain Medicine. 2023;24(1):71-78. doi:10.1093/pm/pnac104
BibTeX
@article{Olusanya2023,
author = {Olusanya, Adedeji and Yearsley, Aaron and Brown, Nicholas and Braun, Samantha and Hayes, Corey and Rose, Evon and Connolly, Brian and Dicks, Madeline and Beal, Colby and Helmonds, Brett and Peace, Wesley and Kirkman, Bryce and Nguyen, Christina and Erickson, Jacob and Nguyen, Gabby and Lukose, Esha and Koek, Wouter and Nagpal, Ameet S and Trbovich, Michelle},
title = {Capsaicin 8% Patch for Spinal Cord Injury Focal Neuropathic Pain, a Randomized Controlled Trial},
journal = {Pain Medicine},
year = {2023},
volume = {24},
number = {1},
pages = {71--78},
doi = {10.1093/pm/pnac104}
}
EUVIMED